Heymann D - Search Results

1

TH1579, MTH1 inhibitor, delays tumour growth and inhibits metastases development in osteosarcoma model.

Moukengue B, Brown HK, Charrier C, Battaglia S, Baud'huin M, Quillard T, Pham TM, Pateras IS, Gorgoulis VG, Helleday T, Heymann D, Berglund UW, Ory B, Lamoureux F. Moukengue B, et al. Among authors: heymann d. EBioMedicine. 2020 Mar;53:102704. doi: 10.1016/j.ebiom.2020.102704. Epub 2020 Mar 7. EBioMedicine. 2020. PMID: 32151797 Free PMC article.

2

Modulation by soluble factors of gelatinase activities released by osteoblastic cells.

Damiens C, Fortun Y, Charrier C, Heymann D, Padrines M. Damiens C, et al. Among authors: heymann d. Cytokine. 2000 Nov;12(11):1727-31. doi: 10.1006/cyto.2000.0765. Cytokine. 2000. PMID: 11052827

3

Influence of metal ion solutions on rabbit osteoclast activities in vitro.

Rousselle AV, Heymann D, Demais V, Charrier C, Passuti N, Baslé MF. Rousselle AV, et al. Among authors: heymann d. Histol Histopathol. 2002 Oct;17(4):1025-32. doi: 10.14670/HH-17.1025. Histol Histopathol. 2002. PMID: 12371129

4

Bisphosphonates: new therapeutic agents for the treatment of bone tumors.

Heymann D, Ory B, Gouin F, Green JR, Rédini F. Heymann D, et al. Trends Mol Med. 2004 Jul;10(7):337-43. doi: 10.1016/j.molmed.2004.05.007. Trends Mol Med. 2004. PMID: 15242682 Review.

5

Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma.

Heymann D, Ory B, Blanchard F, Heymann MF, Coipeau P, Charrier C, Couillaud S, Thiery JP, Gouin F, Redini F. Heymann D, et al. Among authors: heymann mf. Bone. 2005 Jul;37(1):74-86. doi: 10.1016/j.bone.2005.02.020. Bone. 2005. PMID: 15894525

6

Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice.

Ory B, Heymann MF, Kamijo A, Gouin F, Heymann D, Redini F. Ory B, et al. Among authors: heymann d, heymann mf. Cancer. 2005 Dec 1;104(11):2522-9. doi: 10.1002/cncr.21530. Cancer. 2005. PMID: 16270320 Free article.

7

RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells.

Wittrant Y, Lamoureux F, Mori K, Riet A, Kamijo A, Heymann D, Redini F. Wittrant Y, et al. Among authors: heymann d. Int J Oncol. 2006 Jan;28(1):261-9. Int J Oncol. 2006. PMID: 16328004 Free article.

8

Zoledronic acid slows down rat primary chondrosarcoma development, recurrent tumor progression after intralesional curretage and increases overall survival.

Gouin F, Ory B, Rédini F, Heymann D. Gouin F, et al. Among authors: heymann d. Int J Cancer. 2006 Sep 1;119(5):980-4. doi: 10.1002/ijc.21951. Int J Cancer. 2006. PMID: 16570273

9

Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status.

Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F, Heymann D. Ory B, et al. Among authors: heymann d. Mol Pharmacol. 2007 Jan;71(1):333-43. doi: 10.1124/mol.106.028837. Epub 2006 Oct 18. Mol Pharmacol. 2007. PMID: 17050806

10

DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.

Mori K, Le Goff B, Charrier C, Battaglia S, Heymann D, Rédini F. Mori K, et al. Among authors: heymann d. Bone. 2007 Apr;40(4):981-90. doi: 10.1016/j.bone.2006.11.006. Epub 2006 Dec 28. Bone. 2007. PMID: 17196895 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

587 results

Search Page

Filters